Medarex Announces Election of Marc Rubin as New Board Member
Wednesday November 7, 4:00 pm ET
[The name Titan leaves a bad aftertaste (Bucalo is still Chairman), but Rubin has not been there "very" long. I cannot but wonder if Rubin doesn't think his priority should be the resurrection of Titan rather than a board membership at Medarex. No, I don't like this appointment]
PRINCETON, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) today announced that Marc Rubin, M.D. has been elected by the company's Board of Directors to serve as a director on Medarex's Board, effective November 1, 2007.
Dr. Rubin is President and CEO of Titan Pharmaceutical, Inc., a biopharmaceutical company publicly traded on the American Stock Exchange. Prior to joining Titan in October 2007, he was Head of Global Research and Development for Bayer Schering Pharma and a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to his position at Bayer Schering Pharma, Dr. Rubin was a Member of the Executive Board and President of Development for Schering AG, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. His position included responsibility for three Global Business Units. Before joining Schering AG, Dr. Rubin held several positions of increasing responsibility at GlaxoSmithKline, including oversight of the development, approval and commercial strategy for numerous programs. Dr. Rubin completed his clinical training in internal medicine at The Johns Hopkins Hospital and subspecialty training in both oncology and infectious disease at the National Institutes of Health. He received his M.D. from Cornell University Medical College and did his undergraduate work at Cornell University.
"We are very pleased Marc is joining our Board of Directors," said Howard H. Pien, President and CEO of Medarex. "He brings strong industry experience to our Board which will complement the Board's leadership in continuing to guide the company's future growth strategy and value creation." |
